Abstract
Fifty-two patients with refractory lymphoma were prospectively treated with prophylactic T lymphocyte infusion after T cell-depleted allogeneic bone marrow transplantation, to induce graft-versus-lymphoma effect. Thirty-three patients had related donors; 19 had unrelated donors. After transplantation with marrow that had 0.8 ± 0.4 × 105CD3+ cells/kg, T cells up to 1.75 × 106 CD3+ cells/kg were given over 3 months provided ⩾ grade II acute graft-versus-host disease (GVHD) was not seen. The cumulative incidence of grades II–IV acute GVHD was 69%. Twenty of 32 evaluable patients (63%) developed chronic GVHD. Ten patients (19%) died of GVHD. The Kaplan–Meier 5-year overall survival of all patients was 34%. On multivariate analyses, chronic GVHD was significant for relapse (hazard ratio of 1.7, P < 0.05), and for overall survival (hazard ratio 1.4, P < 0.001). Chemosensitivity was significant for relapse only on univariate analysis. Patients who developed chronic GVHD had 4 years median survival, compared with 9 months in patients without chronic GVHD, P < 0.001. The study shows that patients with chronic GVHD have superior survivals, most probably related to a graft-versus-lymphoma effect, which could be modulated by prophylactic T cell infusion.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma New Engl J Med 1995 333: 1540 1545
Horning SJ, Chao NJ, Negrin RS et al. High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: analysis of the Stanford University results and prognostic indices Blood 1997 89: 801 813
Nademanee A, O'Donnell MR, Snyder DS et al. High-dose chemotherapy with or without total body irradiation followed by autologous bone marrow and/or peripheral blood stem cell transplantation for patients with relapsed and refractory Hodgkin's disease: results in 85 patients with analysis of prognostic factors Blood 1995 85: 1381 1390
Burns LJ, Daniels KA, McGlave PB et al. Autologous stem cell transplantation for refractory and relapsed Hodgkin's disease: factors predictive of prolonged survival Bone Marrow Transplant 1995 16: 13 18
Crump M, Smith AM, Brandwein J et al. High-dose etoposide and melphalan, and autologous bone marrow transplantation for patients with advanced Hodgkin's disease: importance of disease status at transplant J Clin Oncol 1993 11: 704 711
Philip T, Armitage JO, Spitzer G et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma New Engl J Med 1987 316: 1493 1498
Appelbaum FR, Sullivan KM, Buckner CD et al. Treatment of malignant lymphoma in 100 patients with chemotherapy, total body irradiation, and marrow transplantation J Clin Oncol 1987 5: 1340 1347
Chopra R, Goldstone AH, Pearce R et al. Autologous versus allogeneic bone marrow transplantation for non-Hodgkin's lymphoma: a case-controlled analysis of the European Bone Marrow Transplant Group Registry data J Clin Oncol 1992 10: 1690 1695
Ratanatharathorn V, Uberti J, Karanes C et al. Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma Blood 1994 84: 1050 1055
Milpied N, Fielding AK, Pearce RM et al. Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease. European Group for Blood and Bone Marrow Transplantation J Clin Oncol 1996 14: 1291 1296
van Besien K, Thall P, Korbling M et al. Allogeneic transplantation for recurrent or refractory non-Hodgkin's lymphoma with poor prognostic features after conditioning with thiotepa, busulfan, and cyclophosphamide: experience in 44 consecutive patients Biol Blood Marrow Transplant 1997 3: 150 156
Dhedin N, Giraudier S, Gaulard P et al. Allogeneic bone marrow transplantation in aggressive non-Hodgkin's lymphoma (excluding Burkitt and lymphoblastic lymphoma): a series of 73 patients from the SFGM database. Societ Francaise de Greffe de Moelle Br J Haematol 1999 107: 154 161
van Besien K, Sobocinski KA, Rowlings PA et al. Allogeneic bone marrow transplantation for low-grade lymphoma Blood 1998 92: 1832 1836
Jones RJ, Ambinder RF, Piantadosi S et al. Evidence of graft-versus lymphoma effect associated with allogeneic bone marrow transplantation Blood 1991 77: 649 653
Lee CK, Gingrich RD, deMagalhaes-Silverman M et al. Prophylactic infusion of T cells for T cell-depleted allogeneic bone marrow transplantation Biol Blood Marrow Transplant 1999 5: 15 27
Johnson BD, Drobyski WR, Truitt RL . Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft versus host disease Bone Marrow Transplant 1993 11: 329 333
Johnson BD, Truitt RL . Delayed infusion of immunocompetent donor cells after bone marrow transplantation breaks graft versus host tolerance and allows for persistent anti-leukemic reactivity without severe graft versus host disease Blood 1995 85: 3302 3312
Juckett M, Rowlings P, Hessner M et al. T cell-depleted allogeneic bone marrow transplantation for high-risk non-Hodgkin's lymphoma: clinical and molecular follow-up Bone Marrow Transplant 1998 21: 893 899
Trigg ME, Petersen A, Erickson C et al. Depletion of T cells from bone marrow for allogeneic transplantation: method for treatment of bone marrow in bulk Exp Hematol 1986 14: 21 26
Lee CK, Gingrich RD, Harman GS et al. Anti-CD3 (OKT3) T cell depletion and add-back: comparative analysis with anti-CD2 (CT2) T cell depletion and add-back in allogeneic bone marrow transplantation Blood 1995 86: 570 (Abstr. 2266)
Cheson BD, Horning SJ, Coiffier B et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group J Clin Oncol 1999 17: 1244 1253
Deeg HJ, Cottler-Fox M . Clinical spectrum and pathophysiology of acute graft-vs.-host disease In: SJ Burakoff, HJ Deeg, J Ferrara, K Atkinson (eds) Graft-vs.-Host Disease Marcel Dekker, Inc: New York, NY 1990 pp 311 338
Glucksberg H, Storb R, Fefer A et al. Clinical manifestations of graft versus host disease in human recipients of marrow from HLA matched sibling donors Transplantation 1974 18: 295 304
Shankar G, Bryson S, Jennings CD et al. Idiopathic pneumonia syndrome after allogeneic bone marrow transplantation in mice. Role of pretransplant radiation conditioning Am J Respir Cell Mol Biol 1999 20: 1116 1124
Juckett M, Rowlings P, Hessner M et al. T cell-depleted allogeneic bone marrow transplantation for high-risk non-Hodgkin's lymphoma: clinical and molecular follow-up Bone Marrow Transplant 1998 21: 893 899
Soiffer RJ, Freedman AS, Neuberg D et al. CD6+ T cell-depleted allogeneic bone marrow transplantation for non-Hodgkin's lymphoma Bone Marrow Transplant 1998 21: 1177 1181
Mandigers CM, Raemaekers JM, Schattenberg AV et al. Allogeneic bone marrow transplantation with T-cell-depleted marrow grafts for patients with poor-risk relapsed low-grade non-Hodgkin's lymphoma Br J Haematol 1998 100: 198 206
Khouri IF, Lee MS, Romaguera J et al. Allogeneic hematopoietic transplantation for mantle-cell lymphoma: molecular remissions and evidence of graft-versus-malignancy Ann Oncol 1999 10: 1293 1299
Naparstek E, Or R, Nagler A et al. T-cell-depleted allogeneic bone marrow transplantation for acute leukaemia using Campath-1 antibodies and post-transplant administration of donor's peripheral blood lymphocytes for prevention of relapse Br J Haematol 1995 89: 506 515
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lee, CK., de Magalhaes-Silverman, M., Hohl, R. et al. Prophylactic T cell infusion after T cell-depleted bone marrow transplantation in patients with refractory lymphoma. Bone Marrow Transplant 29, 615–620 (2002). https://doi.org/10.1038/sj.bmt.1703426
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1703426
Keywords
This article is cited by
-
Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT
Bone Marrow Transplantation (2016)
-
T Cell Immunotherapy for Immune Reconstitution and GVHD Prevention After Allogeneic Hematopoietic Stem Cell Transplantation
Current Stem Cell Reports (2015)
-
Donor lymphocyte infusions: the long and winding road: how should it be traveled?
Bone Marrow Transplantation (2008)